Related Experiment Videos
Thalidomide as an anti-cancer agent
S Kumar1, T E Witzig, S V Rajkumar
1Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Journal of Cellular and Molecular Medicine
|August 10, 2002
Summary
Thalidomide, a drug with a complex history, is now used for specific conditions like erythema nodosum leprosum and certain cancers. Its anti-cancer effects are linked to anti-angiogenesis and anti-TNF alpha activity.
Area of Science:
- Pharmacology
- Oncology
- Immunology
Background:
- Thalidomide, a glutamic acid derivative, was initially a sedative hypnotic before its withdrawal due to teratogenicity.
- Reintroduced for erythema nodosum leprosum and HIV wasting syndrome, its therapeutic applications have expanded under strict regulation.
- Its anti-angiogenic properties prompted investigation into its use for various malignancies.
Purpose of the Study:
- To review the historical background and pharmacological aspects of thalidomide.
- To summarize current knowledge on the mechanisms of thalidomide's anti-neoplastic activity.
- To present results from clinical trials evaluating thalidomide in oncology.
Main Methods:
- Literature review of historical data and clinical trials.
- Analysis of pharmacological studies on thalidomide's mechanisms of action.
- Synthesis of findings from recent oncology clinical trials.
Main Results:
- Thalidomide demonstrates significant anti-myeloma activity, confirmed by recent clinical trials.
- Preliminary trials show promise for thalidomide in treating various other malignant diseases.
- Anti-angiogenic effects are crucial, but other properties also contribute to its anti-tumor activity.
Conclusions:
- Thalidomide possesses multifaceted anti-neoplastic effects beyond its anti-angiogenic properties.
- Its anti-TNF alpha activity supports its evaluation in inflammatory conditions.
- Ongoing research continues to elucidate the complex mechanisms underlying thalidomide's efficacy in cancer treatment.